Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 26, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

Extreme hypofractionation for prostate cancer.

W Robert Lee1

  • 1Duke University School of Medicine, Department of Radiation Oncology, DUMC, Durham, NC 27710, USA. w.robert.lee@duke.edu

Expert Review of Anticancer Therapy
|December 25, 2008
PubMed
Summary

Hypofractionated radiotherapy schedules may improve prostate cancer treatment by matching tumor sensitivity. This study examines extreme hypofractionation using high-dose-rate brachytherapy and stereotactic body radiotherapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Participant Heterogeneity in the Prostate Cancer Biobank of the NRG: An Obstacle to Broadening the Reach of Precision Oncology.

JCO precision oncology·2026
Same author

Correlation of Biochemical Recurrence With Adverse Late Toxic Events Following Prostate Radiation Therapy (COBALT Study): An Individual Patient Data Meta-Analysis of 7 Randomized Trials.

International journal of radiation oncology, biology, physics·2026
Same author

The Radiation Oncology Match in 2025: A New Steady-State?

Practical radiation oncology·2025
Same author

Hypofractionated radiotherapy for prostate cancer (HYDRA): an individual patient data meta-analysis of randomised trials in the MARCAP consortium.

The Lancet. Oncology·2025
Same author

The interplay between acute and late toxicity among patients receiving prostate radiotherapy: an individual patient data meta-analysis of six randomised trials.

The Lancet. Oncology·2025
Same author

The Radiation Oncology Match in 2024: Reason for Optimism.

Practical radiation oncology·2024

Area of Science:

  • Radiation oncology
  • Medical physics

Background:

  • Radiotherapy fractionation aims to optimize tumor control while sparing normal tissues.
  • Recent studies suggest a low alpha/beta ratio (1-3 Gy) for prostate tumors, indicating sensitivity to hypofractionation.
  • Hypofractionation, using fewer, larger doses, could enhance the therapeutic ratio for prostate cancer.

Purpose of the Study:

  • To critically evaluate extreme hypofractionated radiotherapy schedules for prostate cancer.
  • To assess the suitability of high-dose-rate brachytherapy and stereotactic body radiotherapy in this context.

Main Methods:

  • Review of existing literature on prostate tumor alpha/beta ratios.
  • Analysis of extreme hypofractionation schedules (3-5 fractions).
  • Examination of high-dose-rate brachytherapy and stereotactic body radiotherapy as monotherapy approaches.

Main Results:

  • Low alpha/beta ratios in prostate tumors support the rationale for hypofractionation.
  • Extreme hypofractionation (3-5 fractions) is explored via brachytherapy and SBRT.
  • The therapeutic ratio may be improved by matching fractionation to tumor sensitivity.

Conclusions:

  • Hypofractionated radiotherapy, particularly with low alpha/beta ratios, holds promise for prostate cancer treatment.
  • High-dose-rate brachytherapy and stereotactic body radiotherapy represent advanced hypofractionation strategies.
  • Further research is needed to optimize these extreme schedules for clinical benefit.

More Related Videos

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Focal Laser Ablation of Prostate Cancer: An Office Procedure
11:07

Focal Laser Ablation of Prostate Cancer: An Office Procedure

Published on: March 30, 2021

Related Experiment Videos

Last Updated: Jun 26, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Focal Laser Ablation of Prostate Cancer: An Office Procedure
11:07

Focal Laser Ablation of Prostate Cancer: An Office Procedure

Published on: March 30, 2021